460 related articles for article (PubMed ID: 33206991)
1. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
Wright K
Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
[TBL] [Abstract][Full Text] [Related]
2. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Nakajima EC; Vellanki PJ; Larkins E; Chatterjee S; Mishra-Kalyani PS; Bi Y; Qosa H; Liu J; Zhao H; Biable M; Hotaki LT; Shen YL; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2022 Feb; 28(3):446-451. PubMed ID: 34462287
[TBL] [Abstract][Full Text] [Related]
4. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
6. First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
Yang L; Song X; Zeng W; Zheng Z; Lin W
Orphanet J Rare Dis; 2023 Oct; 18(1):326. PubMed ID: 37845696
[TBL] [Abstract][Full Text] [Related]
7. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
Front Public Health; 2022; 10():947375. PubMed ID: 35937220
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
10. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
11. Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Barbier MC; Fengler A; Pardo E; Bhadhuri A; Meier N; Gautschi O
Pharmacoeconomics; 2023 Dec; 41(12):1641-1655. PubMed ID: 37572261
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
15. NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
Adler AI; Slayen S; Stegenga H; Guo Y; Diaz R; Welton NJ; Westwood N; Doull I; Crawley C
Lancet Respir Med; 2022 Oct; 10(10):e92-e93. PubMed ID: 35988573
[No Abstract] [Full Text] [Related]
16. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
17. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
18. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
Nakamura A; Hashimoto M; Kondo N; Matsumoto S; Kuroda A; Minami T; Kitajima K; Kuribayashi K; Kijima T; Hasegawa S
Int J Clin Oncol; 2023 Mar; 28(3):409-415. PubMed ID: 36609928
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]